Why the absence of controlled human data on BPC-157 matters more than people admit — that is the question, and I have not found it answered plainly anywhere I have looked.
I would like to know what people here actually do about absence of controlled human data, as distinct from what is usually recommended. Those have diverged in every other subject I have looked at closely.
Mine is below, with the reasoning, including the parts I am not confident about.
Post #3 put the caveat in the right place and I want to underline it.
Publication patterns in the BPC-157 literature: a large proportion of the evidence comes from one research group. That is not necessarily wrong — one group can do excellent work — but it is worth noting when evaluating the breadth of support for a claim.
Adding it because I spent an afternoon working it out and nobody should have to twice.
Thank you for taking the time. That was more work than a reply usually is.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
Not the whole picture, but the part of it I can speak to.
For anyone arriving from search engines: this subcategory discusses published preclinical work and the absence of published clinical work. It does not endorse or recommend these compounds.
Absence of controlled human data is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is being asked for.
Building on post #57 rather than restating it.
BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a dismissal — it is the state of the literature, and any discussion that starts elsewhere is starting from something that is not there.
Anyone with a larger sample, please post it.
Read the full topic (67 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Stability of BPC-157 in solution: what has been measured
Stability of BPC-157 in solution: what has been measured — setting out what I have, and where I think it stops being reliable. Something about stability of BPC-157 does not reconcile and I would like a second…
|
2 | 805 | 30d | |
|
Reading a preclinical wound-healing model and its relevance to a human tendon
On the subject in the title: Reading a preclinical wound-healing model and its relevance to a human tendon Working notes rather than a conclusion. Posting a small dataset on reading a preclinical…
|
+149 | 160 | 3.3k | 20mo |
|
Why plausible mechanism is not evidence of effect — one year on
The question in the title: Why plausible mechanism is not evidence of effect — one year on I will give what I have already checked below so nobody repeats it. What changes if the standard account of plausible…
|
+3 | 7 | 3.6k | 13mo |
|
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about…
|
+50 | 55 | 7.8k | 2d |
|
Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset
Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Reading a…
|
+64 | 69 | 27k | 4mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
The "under review" status pill and when a moderator applies it — a second dataset
The "under review" status pill and when a moderator applies it — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. A question about how this site should cite…
|
+50 | 54 | 1.4k | 11mo |
|
Ipamorelin selectivity claims and where they came from — a second dataset
Posting this under the heading it deserves: Ipamorelin selectivity claims and where they came from — a second dataset Everything below is what sits behind that. Posting a small dataset on Ipamorelin…
|
2 | 27k | 14mo | |
|
Melanocortin agonists: mechanism and the documented adverse profile
Melanocortin agonists: mechanism and the documented adverse profile — setting out what I have, and where I think it stops being reliable. Melanocortin agonists, and specifically the version of it that the…
|
+7 | 11 | 5.5k | 20mo |
|
Follow-up: Evidence quality in the secretagogue literature: an honest assessment
On the subject in the title: Evidence quality in the secretagogue literature: an honest assessment Working notes rather than a conclusion. A follow-up question about Evidence quality that I did not know to…
|
+20 | 24 | 18k | 4mo |
|
The retatrutide phase 2 obesity paper, read closely
Posting this under the heading it deserves: The retatrutide phase 2 obesity paper, read closely Everything below is what sits behind that. Retatrutide phase 2 obesity paper, from the point of view of someone…
|
2 | 65k | 10mo |